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Abstract
Since the advent of 123I-meta-iodobenzylguanidine（MIBG）in 1990s, it has been widely used in clinical
practice in Japan. Based on the wide range of clinical applications, 123I MIBG is now incorporated in
Japanese Circulation Society)s guidelines of nuclear cardiology. The major role of 123I MIBG has been in
determination of severity and prognostic evaluation of heart failure. In addition, assessment of the
treatment by various types of medications has been the second major role of 123 I MIBG imaging.
Compared with the conventional clinical parameters of heart failure, additive values of 123I MIBG
depend on how it reflects the patient condition more accurately, and how it relates to improvement in
the patient outcome. 123 I MIBG is also now available for cardiac imaging in the USA and Europe.
Unified methodology and further studies focusing on clinical decision-making are the next required
steps to document MIBG utility.
Keywords: 123I meta-iodobenzylguanidine（MIBG）, Chronic heart failure, Decision making, Prognosis,
therapeutic intervention




approved for clinical use by Japanese Ministry of
Health and Welfare in Japan in 1992, and has been
commercially available for 23 years. 123 I MIBG（MyoMIBG,
FUJIFILM RI Pharma, Co. Ltd, Tokyo, Japan）is
included in Japanese Circulation Society（JCS）clinical
guidelines of nuclear cardiology（1）, and has been one of
the well-recognized radiopharmaceuticals. Clinical use
of 123 I MIBG is much more common in Japan than
Europe, where the product has been commercially
available for a similar length of time. In contrast, 123 I
MIBG was only approved by Food and Drug Adminis-
tration in the USA for use in cardiology in 2013.
The broad clinical approval of 123 I MIBG in Japan,
encompassing cardiac diseases as a whole, has encour-
aged its use in a wide variety of cardiac conditions. The
applications have included assessment of denervated
but viable myocardium after acute myocardial infarc-
tion, primary and secondary cardiomyopathies, and
serious arrhythmic diseases, in addition to the most
widely used indication for chronic heart failure（CHF）
（1）. New indications of Lewy-body diseases in neurolo-
gy field were added in the late 1990s.
Prognostic use of 123I MIBG in heart failure
The primary indication listed in the JCS clinical
practice guidelines is assessment of severity of heart
failure and prognosis for patients with heart failure
（Class I: conditions for which there is evidence or
general agreement that a given test is useful and
effective）. Concerning the utility of prognostic evalua-
tion, the studies have unanimously concluded that low
values of the heart-to-mediastinum ratio（HMR）, a
simple average count ratio of cardiac and mediastinal
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regions, was related to poor prognosis. Another para-
meter often used was washout rate or MIBG clearance
from the heart. The endpoints included cardiac death
including deaths from pump failure, sudden cardiac
death and acute myocardial infarction, as well as
exacerbation of CHF symptoms（2-5）. In addition, a
number of multicenter studies and meta-analyses have
been performed in Japan, Europe and USA（6-10）.
These studies have indicated that HMR with 123I MIBG
had independent and powerful prognostic value. The
most appropriate threshold of HMR for discriminating
good and poor prognosis has varied among studies,
ranging from 1.2 to 1.8 depending on the included
patients Fbackground, disease severity, and outcome
endpoints, although simple dichotomization of HMRmay
not be the best practice（11）. While CHF symptoms and
left ventricular function, and markers such as b-type
natriuretic peptide（BNP）are also important predic-
tors of cardiac events, numerous studies have shown
that 123 I MIBG imaging provides additional prognostic
information. It has been more difficult to establish
whether MIBG imaging adds clinical value over
conventional diagnostic approaches, in spite of its
documented additive value over conventional para-
meters using multiple statistical methods.
The superiority of the strategy of adding MIBG has
been verified using statistical analysis techniques such
as multivariate proportional hazards and logistic regres-
sion, receiver-operating characteristic curve analysis
and net reclassification improvement（NRI）analysis.
In the sub-analysis of ADMIRE-HF study, additive
value of MIBG was mainly to reclassify patients into
severer CHF groups（12）. The NRI was 22.7% with
14.9% of subjects who died reclassified into a higher risk
category than suggested by Seattle Heart Failure Model
score alone. On the other hand, analyses of the Japanese
pooled database based on six prospective cohort studies
have shown that the model incorporating 123 I MIBG
could reclassify patients better into the less severe CHF
groups compared with the model without MIBG（7）.
The NRI using the model with 123I MIBG was 17.5% with
10.2% reclassified into lower risks for surviving
patients. Although the NRI results from these 2 different
patient groups initially appear contradictory, they in fact
suggest that the benefits of MIBG imaging may depend
on the study population; the potential effective utility
of 123I MIBG is in characterizing the dominant compo-
nent of the CHF population, whether the pretest
likelihood of an event in that group is low or high.
Based upon the Japanese meta analysis population,
the most potent combination of predictors was New
York Heart Association（NYHA）functional class, age,
sex, left ventricular ejection fraction（LVEF）, and 123I
MIBG HMR（6-8,13）（Fig. 1）. Although BNP was also
included as a good predictor of cardiac events in these
studies, BNP level is known to respond to short-term
functional changes, while MIBG is typically relatively
stable during hospital course.
123I MIBG for the assessment of medical treatment
The second indication listed in the JCS guidelines is
assessment of effect of heart failure treatment（Class
IIa: conditions for which there is conflicting evidence or
a divergence of opinion about the usefulness of a test,
but weight of evidence/opinion is in favor of usefulness）.
In clinical practice, improvement in symptoms and
cardiac function is a salient marker to evaluate
therapeutic effects. However, 123 I MIBG imaging pro-
vides a means to document one of the physiological
mechanisms for clinical improvement in CHF patients,
recovery of sympathetic neuronal function in response
to moderation of sympathetic and renin-angiotensin-al-
dosterone system overactivity. The research question
has been whether improvement of sympathetic function
after medications was associated with better clinical
course of CHF and eventually related to favorable
outcomes. KasamaFs review article in this issue of
journal, Annals of Nuclear Cardiology, summarized the
use of 123 I MIBG regarding assessment of medical
treatments（14）. He has extensively investigated the
utility of 123I MIBG associated with interventions with
medications, including beta blockers, angiotensin-con-
verting enzyme inhibitors, angiotensin II receptor
blockers, aldosterone blockers, diuretics, and others.
These results indicated that therapeutic interventions
affect sympathetic innervation in a variety of ways in
addition to the improvement of left ventricular function.
As most modern CHF therapeutics act directly or
indirectly on the autonomic nervous system and the
renin-angiotensin-aldosterone system, the consistent
finding of improvement of MIBG cardiac uptake with
use of almost all these medications is important
validation of their therapeutic effectiveness. However,
heart failure treatment guidelines based upon rando-
mized clinical trials do not include MIBG imaging as an
adjunct to assist in decision-making. As such, further
studies are needed to explore how MIBG could be used
to improve decision-making for optimal medical ther-
apy. For example, in almost every clinical trial there is a
subset of patients who do not benefit from the therapy
under study. Perhaps MIBG imaging would be able to
identify such non-responders in clinical practice, thus
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avoiding extended courses of ultimately ineffective
therapy. At present, cardiologists often think that
123I-MIBG results are interesting but not essential for
making treatment decisions. Although 123I MIBG is
included in current JCS nuclear cardiology guidelines,
123I MIBG will only be added into cardiology practice
guidelines of CHF if further research documents
improvement in clinical outcomes among patients who
underwent the imaging procedure.
Future directions of 123I MIBG
Standardized methods for data acquisition and
processing are required. The method for calculating
HMR is simple, but the numerical result is dependent on
technical factors that can only be accounted for using
cross-calibration techniques to compensate for camera-
collimator variations. In Japan, research has been
performed on this issue, and more than 100 hospitals are
now able to use standardized HMR based on a cross-
calibration phantom study（15）. Additional studies to
extend the standardization of HMR to cadmium zinc
telluride（CZT）cameras, on which conventional anter-
ior planar images cannot obtained, will also be required.
Despite improvements in therapies over the past
several decades, mortality from CHF in Japan, USA and
Europe remains high, comparable to that of many types
of cancer. Data indicate that the reliability of mortality
risk estimation is enhanced using 123 I MIBG, allowing
more accurate identification of low-risk patients（for
example those with HMR ＞2. 0 and annual mortality
risk ＜1%）who are unlikely to benefit from costly
cardiac device treatment（Fig. 2）. On the other hand,
patients who have low HMR and high mortality risk
may be more effectively identified for referral for
cardiac device therapy such as implantable cardiover-
ter-defibrillator（ICD）or cardiac resynchronization
therapy combined with ICD. In addition, rather than
evaluating the effect of medications on individual
parameters such as LVEF or MIBG HMR, it might be
more appropriate to quantify risk reduction in terms of
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Fig. 1
123I MIBG studies in two patients with dilated cardiomyopathy（DCM）. Upper panel: a 54-year old man with
DCM in NYHA class III. 123I MIBG late HMR was 1.6, and LVEF was 19%. The estimated event risk was high;
44% for 5 years（13）. In this patient, CRT-D device was implanted and experienced an episode of ventricular
tachycardia after MIBG study. Lower panel: a 33-year old woman with DCM in NYHA class II. Her LVEF was
23%, and 123I MIBG late HMR was calculated to be 2.7. The estimated event risk was 1% for 5 years, indicating
good prognosis.
the estimated mortality rate. Future prospective cohort
studies will hopefully confirm the validity of this
hypothesis.
In the current era of multimodality imaging, echocar-
diography, cardiac X-ray computed tomography, and
magnetic resonance imaging have specific unique roles
to determine etiology and diagnose functional status to
aid in the management of CHF. Numerous nuclear
cardiology studies, including myocardial perfusion
imaging with ECG-gating, fatty acid imaging with 123I
beta-methyliodophenyl pentadecanoic acid（BMIPP）,
18F fluorodeoxyglucose（FDG）, and 123I MIBG are also
available（16）. The ongoing challenge for cardiologists
and radiologists/nuclear medicine physicians is to select
the most appropriate procedures that will yield the
necessary clinical information in a cost-effective and
patient-centric manner.
Conclusion
123I MIBG imaging is a readily available and powerful
tool to predict prognosis in CHF. The next step will be to
improve the integration of MIBG imaging into clinical
practice in order to enhance effective risk stratification
and achieve more cost-effective therapeutic approaches
in CHF.
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